{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T16:27:28Z","timestamp":1794587248981,"version":"4.9.1"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"25","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medical Science Research Project of Hebei","award":["20242094"],"award-info":[{"award-number":["20242094"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,19]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Fibrates like bezafibrate are renally excreted and can cause rhabdomyolysis in chronic kidney disease (CKD). This report describes bezafibrate-associated rhabdomyolysis in a patient with diabetic kidney disease and successful transition to tafolecimab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>Ten days after self-initiating bezafibrate (0.2\u2009g thrice daily), a 71-year-old female patient with diabetes, hypertension, CKD, and dyslipidemia complained of fatigue, sweating, and myalgia. Tests revealed hypokalemia, renal failure (creatinine 329.3 \u03bcmol\/L), and increased creatine kinase (4865 U\/L).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>After ruling out other causes, a peak creatine kinase of 6419 U\/L (38\u00d7 upper normal limit) and myalgia were used to diagnose bezafibrate-associated rhabdomyolysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>The use of bezafibrate was stopped. Hepatoprotection, renal protection, bicarbonate, potassium correction, and eventually a switch to subcutaneous tafolecimab 150\u2009mg every 2 weeks were all part of the supportive care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>Myalgia went away in 6 days, and by the time of discharge, creatine kinase had returned to normal from 6419 to 54 U\/L. Following tafolecimab, low-density lipoprotein cholesterol (4.18 to 2.93 mmol\/L) was lower, and muscle enzymes were normal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>Bezafibrate may result in severe rhabdomyolysis in diabetic CKD, particularly when combined with nifedipine (a CYP3A4 inhibitor) and reduced renal clearance. Tafolecimab\u2019s nonrenal metabolism and low myotoxicity make it a safe and efficient substitute.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049269","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T06:01:00Z","timestamp":1782108060000},"page":"e49269","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Bezafibrate-associated rhabdomyolysis in a patient with diabetic kidney disease: A case report and successful transition to tafolecimab"],"prefix":"10.1097","volume":"105","author":[{"given":"Yiping","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Hebei Medical University, Shijiazhuang, Hebei, China"},{"name":"Department of Endocrinology, Harrison International Peace Hospital, Hengshui, Hebei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinrong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Harrison International Peace Hospital, Hengshui, Hebei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hebei Medical University, Shijiazhuang, Hebei, China"},{"name":"Department of Endocrinology, Harrison International Peace Hospital, Hengshui, Hebei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6465-8651","authenticated-orcid":false,"given":"Wei","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Harrison International Peace Hospital, Hengshui, Hebei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261113","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/mus.10053","article-title":"Rhabdomyolysis: a review.","volume":"25","author":"Warren","year":"2002","journal-title":"Muscle Nerve"},{"key":"R2-20261113","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00415-019-09185-4","article-title":"A systematic review on the definition of rhabdomyolysis.","volume":"267","author":"Stahl","year":"2020","journal-title":"J Neurol"},{"key":"R4-20261113","doi-asserted-by":"crossref","first-page":"e43009","DOI":"10.1097\/MD.0000000000043009","article-title":"Severe rhabdomyolysis induced by bezafibrate in the treatment of severe acute pancreatitis with hyperlipidemia: a case report.","volume":"104","author":"Geng","year":"2025","journal-title":"Medicine (Baltimore)"},{"key":"R5-20261113","first-page":"512","article-title":"Acute rhabdomyolysis and hemoglobin reduction after bezafibrate overdose in hyperlipidemic patients on hemodialysis.","volume":"68","author":"Bedani","year":"1994","journal-title":"Nephron"},{"key":"R6-20261113","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.21037\/atm-21-3660","article-title":"Causes and outcome of rhabdomyolysis in patients admitted to medical wards in the Prince of Wales Hospital.","volume":"9","author":"Zeng","year":"2021","journal-title":"Ann Transl Med"},{"key":"R7-20261113","first-page":"393","article-title":"Rhabdomyolysis caused by overdose of bezafibrate in a patient with uremia.","volume":"17","author":"Yang","year":"2015","journal-title":"Adverse Drug React J"},{"key":"R8-20261113","first-page":"1448","article-title":"Rhabdomyolysis and lipid-lowering drugs.","volume":"293","author":"Tenenbaum","year":"2005","journal-title":"JAMA"},{"key":"R9-20261113","first-page":"73","article-title":"Fenofibrate-induced rhabdomyolysis in two uremic patients: a case report [in Chinese].","volume":"41","author":"Li","year":"2013","journal-title":"Chin J Clin"},{"key":"R10-20261113","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s00228-009-0723-7","article-title":"Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report.","volume":"65","author":"Wu","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"R11-20261113","first-page":"828","article-title":"A case of severe acute rhabdomyolysis induced by bezafibrate [in Chinese].","volume":"34","author":"Liu","year":"2019","journal-title":"Chin Circ J"},{"key":"R12-20261113","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12916-023-02797-8","article-title":"Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2).","volume":"21","author":"Chai","year":"2023","journal-title":"BMC Med"},{"key":"R13-20261113","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s43044-025-00653-z","article-title":"Efficacy and safety of tafolecimab a new PCSK9 inhibitor in patients with hyperlipidemia: a systematic review and meta-analysis of randomized controlled trials.","volume":"77","author":"Ahmed","year":"2025","journal-title":"Egypt Heart J"},{"key":"R14-20261113","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s40265-025-02167-z","article-title":"Tafolecimab, a third monoclonal antibody for PCSK9 as the novel lipid-lowering drug around the world: a narrative review.","volume":"85","author":"Liu","year":"2025","journal-title":"Drugs"},{"key":"R15-20261113","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jacasi.2023.04.011","article-title":"Tafolecimab in Chinese patients with hypercholesterolemia (CREDIT-4): a randomized, double-blind, placebo-controlled phase 3 trial.","volume":"3","author":"Qi","year":"2023","journal-title":"JACC Asia"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049269","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T16:01:43Z","timestamp":1794585703000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":14,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049269","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"2026-03-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}